Company Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.
It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings.
The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Country | United States |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Dr. Yuval Cohen Ph.D. |
Contact Details
Address: 500 River Ridge Drive Norwood, Massachusetts 02062 United States | |
| Phone | 617-963-0103 |
| Website | corbuspharma.com |
Stock Details
| Ticker Symbol | CRBP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001595097 |
| CUSIP Number | 21833P103 |
| ISIN Number | US21833P3010 |
| Employer ID | 46-4348039 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yuval Cohen Ph.D. | Chief Executive Officer and Director |
| Sean F. Moran CPA, M.B.A. | Chief Financial Officer |
| Lindsey Smith | Head of Corporate Communications and Patient Advocacy |
| Christina Bertsch | Head of Human Resources |
| Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 2, 2024 | ARS | Filing |
| Apr 2, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 22, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2024 | EFFECT | Notice of Effectiveness |
| Mar 20, 2024 | 8-K | Current Report |
| Mar 20, 2024 | 10-K/A | [Amend] Annual report |
| Mar 20, 2024 | 424B3 | Prospectus |